Coronavirus Information for the UC San Diego Community

Our leaders are working closely with federal and state officials to ensure your ongoing safety at the university. Stay up to date with the latest developments. Learn more.

Prediction of seriniquinone-drug interactions by in vitro inhibition of human cytochrome P450 enzymes

TitlePrediction of seriniquinone-drug interactions by in vitro inhibition of human cytochrome P450 enzymes
Publication TypeJournal Article
Year of Publication2020
Authorsda Silva R.M, Carrao D.B, Habenschus M.D, Jimenez P.C, Lops N.P, Fenical W, Costa-Lotufo L.V, de Oliveira A.RM
Volume65
Date Published2020/06
Type of ArticleArticle
ISBN Number0887-2333
Accession NumberWOS:000524349000062
Keywordscytochrome P450; Human liver microsomes; in vitro metabolism; Inhibition mechanisms; mechanisms; Natural product-drug interaction; seriniquinone; Toxicology
Abstract

Seriniquinone is a secondary metabolite isolated from a rare marine bacterium of the genus Serinicoccus. This natural quinone is highlighted for its selective cytotoxic activity toward melanoma cancer cells, in which rapid metastatic properties are still a challenge for clinical treatment of malignant melanoma. The progress of seriniquinone as a promising bioactive molecule for drug development requires the assessment of its clinical interaction potential with other drugs. This study aimed to investigate the in vitro inhibitory effects of seriniquinone on the main human CYP450 isoforms involved in drug metabolism. The results showed strong inhibition of CYP1A2, CYP2E1 and CYP3A, with IC50 values up to 1.4 mu M, and moderate inhibition of CYP2C19, with IC50 value > 15 mu M. Detailed experiments performed with human liver microsomes showed that the inhibition of CYP450 isoforms can be explained by competitive and non-competitive inhibition mechanisms. In addition, seriniquinone demonstrated to be an irreversible and time-dependent inhibitor of CYP1A2 and CYP3A. The low inhibition constants values obtained experimentally suggest that concomitant intake of seriniquinone with drug metabolized by these isoforms should be carefully monitored for adverse effects or therapeutic failure.

DOI10.1016/j.tiv.2020.104820
Student Publication: 
No